Inhibitory effect of Phlai capsules on skin test responses among allergic rhinitis patients: a randomized, three-way crossover study
Autor: | Thaweephol Dechatiwongse Na Ayudhya, Pattara Tanticharoenwiwat, Sittichai Koontongkaew, Weena Jiratchariyakul, Prapasri Kulalert, Ruedee Soawakontha, Orapan Poachanukoon, Prakongsiri Booncong |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
0301 basic medicine medicine.medical_specialty medicine.medical_treatment Histamine Antagonists Loratadine medicine.disease_cause Gastroenterology law.invention 03 medical and health sciences chemistry.chemical_compound Double-Blind Method Randomized controlled trial Zingiberaceae law Internal medicine Anti-Allergic Agents medicine Animals Humans Skin Skin Tests House dust mite Mites Cross-Over Studies integumentary system biology Plant Extracts business.industry Repeated measures design Aeroallergen General Medicine Allergens biology.organism_classification Rhinitis Allergic Crossover study 030104 developmental biology chemistry Anesthesia Antihistamine business Histamine Phytotherapy medicine.drug |
Zdroj: | Journal of Integrative Medicine. 15:462-468 |
ISSN: | 2095-4964 |
Popis: | Background Zingiber cassumunar Roxb., commonly known as Phlai in Thai, has been used as a traditional medicine in Thailand for the treatment of various diseases, including inflammation and chronic airway disease. Objective The purpose of this study was to assess the antihistaminic effect of Phlai on skin testing. Design, Setting, Participants and Intervention This was a randomized, open-label, three-way crossover study. Twenty allergic rhinitis (AR) patients were enrolled. In randomized sequence, patients received a single dose of Phlai capsules (100 or 200 mg) or loratadine (10 mg) with a washout period of 1 week between each treatment. Main Outcome Measures Skin prick testing for histamine and common aeroallergen (house dust mite) were performed before treatment and after 1, 2, 3, 4, 6, 8, 12 and 24 hours of treatment. The main treatment outcomes were the mean wheal and flare responses to the skin prick test after treatment. Results Both 100 mg and 200 mg Phlai doses suppressed wheal and flare responses to house dust mite allergen, but only 200 mg of Phlai capsules significantly suppressed wheal and flare responses to histamine. Repeated measures analysis of variance showed that loratadine caused more wheal and flare suppression than Phlai capsules in responses to the histamine skin prick test. However, there were no significant differences among the effects of 100 mg Phlai capsules, 200 mg Phlai capsules and loratadine in suppression of wheal and flare induced by the mite skin prick test. Both doses of Phlai were well-tolerated with no adverse events. Conclusion Both 100 mg (compound D 4 mg) and 200 mg (compound D 8 mg) Phlai capsules, when taken as a single therapeutic dose, inhibited skin reactivity to histamine and mite skin prick tests in AR patients. Trial Registration Thai clinical trial registry (TCTR20160510001). |
Databáze: | OpenAIRE |
Externí odkaz: |